title: Human adrenomedullin gene delivery protects against cardiac hypertrophy, fibrosis, and renal damage in hypertensive dahl salt-sensitive rats.
abstract: Adrenomedullin (AM) is a potent vasodilator expressed in tissues relevant to cardiac and renal functions. Our previous study showed that delivery of the human AM gene in the form of naked DNA caused a prolonged reduction of blood pressure in genetically hypertensive rats. In this study, we evaluated potential protective effects of adenovirus-mediated AM gene delivery on salt-induced cardiorenal lesions in hypertensive Dahl saltsensitive (DSS) rats. Adenovirus carrying the human AM cDNA under the control of the cytomegalovirus promoter-enhancer (Ad.CMV-hAM) was generated by homologous recombination of E. coli. Expression of recombinant human AM was detected by a radioimmunoassay in the medium of human embryonic kidney 293 cells transfected with Ad.CMV-hAM. A single intravenous injection of Ad.CMV-hAM caused a significant reduction of systolic blood pressure for 4 weeks in DSS rats compared with control rats with or without injection of adenovirus carrying the green fluorescent protein gene. AM gene delivery significantly reduced left ventricular mass and urinary protein, increased cAMP levels, and enhanced renal function as evidenced by increases in glomerular filtration rate and renal blood flow. Morphological investigations showed that AM gene transfer reduced cardiomyocyte diameter and interstitial fibrosis in the heart as well as glomerular sclerosis, tubular disruption, and protein cast accumulation in the kidney. Expression of human AM mRNA was identified in rat heart, kidney, lung, liver, and aorta, and immunoreactive human AM levels were measured in rat plasma and urine. These results indicate that human AM gene delivery protects against salt-induced hypertension and cardiac and renal lesions in DSS rats via activation of cAMP as a second messenger. These findings provide new insights into the role of AM in salt-induced hypertension and may have implications in therapeutic applications to salt-related cardiovascular and renal diseases.
authors.affiliation: Department of Biochemistry and Molecular Biology, Medical University of South Carolina, Charleston, SC 29425, USA.
authors.forename: J J
authors.initials: JJ
authors.lastname: Zhang
authors.forename: H
authors.initials: H
authors.lastname: Yoshida
authors.forename: L
authors.initials: L
authors.lastname: Chao
authors.forename: J
authors.initials: J
authors.lastname: Chao
mesh_terms: D000256:Adenoviridae / Q000235:genetics; D053607:Adrenomedullin; D000818:Animals; D001794:Blood Pressure / Q000187:drug effects; D006332:Cardiomegaly / Q000473:pathology / Q000517:prevention & control*; D002460:Cell Line / Q000821:virology; D000242:Cyclic AMP / Q000652:urine; D005355:Fibrosis / Q000517:prevention & control; D015316:Genetic Therapy / Q000379:methods; D006801:Humans; D006973:Hypertension / Q000150:complications* / Q000188:drug therapy / Q000235:genetics; D007668:Kidney / Q000473:pathology*; D007677:Kidney Function Tests; D008297:Male; D010455:Peptides / Q000235:genetics* / Q000494:pharmacology*; D011507:Proteinuria / Q000175:diagnosis; D051381:Rats; D020303:Rats, Inbred Dahl; D011994:Recombinant Proteins / Q000235:genetics / Q000378:metabolism; D012492:Salts / Q000009:adverse effects
chemical_list: D010455:Peptides; D011994:Recombinant Proteins; D012492:Salts; D053607:Adrenomedullin; D000242:Cyclic AMP